These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities. Stefanic Anderluh P; Anderluh M; Ilas J; Mravljak J; Sollner Dolenc M; Stegnar M; Kikelj D J Med Chem; 2005 May; 48(9):3110-3. PubMed ID: 15857114 [TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. Chackalamannil S; Wang Y; Greenlee WJ; Hu Z; Xia Y; Ahn HS; Boykow G; Hsieh Y; Palamanda J; Agans-Fantuzzi J; Kurowski S; Graziano M; Chintala M J Med Chem; 2008 Jun; 51(11):3061-4. PubMed ID: 18447380 [TBL] [Abstract][Full Text] [Related]
12. G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents. Chackalamannil S Curr Top Med Chem; 2003; 3(10):1115-23. PubMed ID: 12769712 [TBL] [Abstract][Full Text] [Related]
13. Exploration of a new series of PAR1 antagonists. Planty B; Pujol C; Lamothe M; Maraval C; Horn C; Le Grand B; Perez M Bioorg Med Chem Lett; 2010 Mar; 20(5):1735-9. PubMed ID: 20137929 [TBL] [Abstract][Full Text] [Related]
14. Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist. Dumas M; Nadal-Wollbold F; Gaussem P; Perez M; Mirault T; Létienne R; Bourbon T; Grelac F; Le Grand B; Bachelot-Loza C Br J Pharmacol; 2012 Mar; 165(6):1827-1835. PubMed ID: 21913899 [TBL] [Abstract][Full Text] [Related]
15. Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. Ahn HS; Chackalamannil S; Boykow G; Graziano MP; Foster C Curr Pharm Des; 2003; 9(28):2349-65. PubMed ID: 14529396 [TBL] [Abstract][Full Text] [Related]
16. Antithrombotic drugs. Treat Guidel Med Lett; 2011 Oct; 9(110):61-6; quiz 2 p following 66. PubMed ID: 21941228 [No Abstract] [Full Text] [Related]
17. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions. Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424 [TBL] [Abstract][Full Text] [Related]
18. Advances in antithrombotic agents. Chakrabarti R; Das SK Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):175-85. PubMed ID: 17630943 [TBL] [Abstract][Full Text] [Related]
19. Total steroidal alkaloids from Veratrum patulum L. Inhibit platelet aggregation, thrombi formation and decrease bleeding time in rats. Song Q; Wang S; Zhao W J Ethnopharmacol; 2012 May; 141(1):183-6. PubMed ID: 22366682 [TBL] [Abstract][Full Text] [Related]
20. M-AAA-thrombin: potent anticoagulant and antiplatelet thrombin derivative with differential affinity for factor VIII and PAR1. Hosokawa K; Matsuda H; Ohnishi T; Gonda M; Koide T Thromb Res; 2010 Nov; 126(5):447-53. PubMed ID: 20870278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]